Navigation Links
Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
Date:8/3/2009

omib and dexamethasone in heavily pre-treated patients with relapsed and refractory disease. Given this positive data and our favorable experience overall with perifosine in this setting, we are hopeful that the upcoming Phase 3 trial will demonstrate clinical benefit for our patients with less advanced myeloma."

Ron Bentsur, Chief Executive Officer of Keryx, stated, "We'd like to thank the FDA and Drs. Paul Richardson and Ken Anderson for their substantial input and guidance during this process. Achievement of this KRX-0401 SPA is a major developmental milestone for Keryx." Mr. Bentsur continued, "We are excited to be moving forward with this very promising compound which we believe is the most advanced PI3K/Akt pathway inhibitor in clinical development."

Phase 3 Design

The Phase 3 trial is a randomized (1:1), double-blind trial comparing the efficacy and safety of KRX-0401 to placebo when combined with bortezomib and dexamethasone in approximately 400 patients with relapsed or relapsed / refractory multiple myeloma. Patients must have been previously treated with both bortezomib (VELCADE((R))) and an immunomodulatory agent (REVLIMID((R)) or THALIDOMID((R))), and been previously treated with one to four prior lines of therapy. The primary endpoint is progression-free survival and secondary endpoints include overall response rate, overall survival and safety.

KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris, Inc. in the United States, Canada and Mexico.

About Multiple Myeloma

Multiple myeloma, a cancer of the plasma cell, is an incurable but treatable disease. Multiple myeloma is the second most-common hematologic cancer, representing 1% of all cancer diagnoses and 2% of all cancer deaths. According to the American Cancer Society, in 2009 there will be an estimated 20,580 new cases of multiple myeloma and an estimated 10,50
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
2. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
3. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
5. Keryx Biopharmaceuticals Receives Nasdaq Notification
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
7. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
9. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
10. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
11. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ... one of two inventors from Miller Place, N.Y. "I specialize in manual therapy, ... discomfort. In addition, it can be used for additional muscle dysfunction throughout the ...
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder and President of ... increase acceptance of the chiropractic field in the military. All too often VA hospitals ... Chiropractic was made available to the VA program over a decade ago, the reality ...
(Date:8/29/2015)... ... ... ProDrop Particles includes over 40 particle backdrops designed for use in ... users can shrink and stretch in the Final Cut Pro X timeline. Choose from ... scale, speed, range, and flare attributes with intuitive controls found in the top-right inspector ...
(Date:8/29/2015)... ... August 29, 2015 , ... The popular television program VOICES IN AMERICA, ... that it will be devoting an entire short segment to the subject of diabetes. ... the globe on a daily basis, but recent advancements in medical science may prove ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a growing ... Hospital recently transitioned management companies to partner with Wound Care Advantage (WCA) to ... wound center. , Transitioning wound care management providers can be a complex ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... SUNDAY, Dec. 11 (HealthDay News) -- A drug called ... cell anemia can also help young children with the disease, ... younger than 4 years old who took the medication had ... with fever and need for transfusions, the study found. ...
... study has found that alcohol consumption directly impacts a person,s intention ... drink, the stronger becomes your intention to engage in unsafe sex. ... HIV infection, and it is a main risk factor for the ... to prevent unsafe sex, HIV incidence in most high income countries ...
... Giving low-dose aspirin to patients after they,ve received stronger blood ... odds of redeveloping the clots, a new study finds. ... include both the leg clots known as deep-vein thromboses, or ... pulse, shortness of breath, chest pain and even death. ...
... protein that was a primary mediator of the birth defects caused ... myeloma , says the study,s senior investigator, Keith Stewart, M.B., ... presented the results at the 53rd annual meeting of the ... thalidomide achieved infamy in the early 1960s as the cause of ...
... December 10, 2011) Symptoms improved significantly in adults ... treatment with gene therapy developed by researchers at St. ... be safe in a clinical trial conducted at the ... findings of the six-person study mark the first proof ...
... , FRIDAY, Dec. 9 (HealthDay News) -- Flu vaccination ... to protect your health during the flu season, but too ... often shrug off concerns about the flu, yet every year ... than 200,000 to the hospital and killing thousands," Dr. Thomas ...
Cached Medicine News:Health News:Adult Sickle Cell Drug May Benefit Kids, Too 2Health News:Adult Sickle Cell Drug May Benefit Kids, Too 3Health News:Alcohol can lead to unsafe sex: It's official 2Health News:Low-Dose Aspirin After Lung Clot Could Prevent Recurrence 2Health News:Low-Dose Aspirin After Lung Clot Could Prevent Recurrence 3Health News:Mayo Clinic: How patients will respond to immunomodulator therapy for multiple myeloma 2Health News:Gene therapy achieves early success against hereditary bleeding disorder 2Health News:Gene therapy achieves early success against hereditary bleeding disorder 3Health News:Americans Encouraged to Get Flu Vaccine 2
(Date:8/28/2015)... , Aug. 28, 2015 ... and Dr. Ra from Biostar , Published in ... 30% increase of lifespan through multiple IV administration of ... vitality, and life expectancy found , Commercialization within ... have determined the possibility that adult mesenchymal stem cells ...
(Date:8/27/2015)... 2015  The Academy of Managed Care Pharmacy ... (FDA,s) draft guidance and proposed rule that calls ... bear a nonproprietary name with an FDA-designated suffix. ... decision from the FDA on the naming issue ... urging the agency to use the same nonproprietary ...
(Date:8/27/2015)... According to a new market research report "Medical Lifting ... ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, Reusable), End User ... Medical Lifting Sling Market is poised to reach USD 706.0 Million ... of 11.4 % from 2015 to 2020. , ... ables and 65 F igures ...
Breaking Medicine Technology:Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4
... Provides Tolerable and Effective Symptom Control, ... SHP, Nasdaq:,SHPGY, TSX: SHQ), the global specialty ... study of DAYTRANA(TM) (methylphenidate,transdermal system), the Attention ... provided significant ADHD tolerability,and symptom control improvement ...
... Anti-Tumor Activity of NKTR-102 Associated With Increased ... Tumor Tissue to the Active Metabolite of ... Nektar Therapeutics,(Nasdaq: NKTR ) presented positive ... NKTR-102 (PEG-irinotecan) at the AACR-NCI-EORTC,International Conference in ...
Cached Medicine Technology:Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 2Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 3Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 4Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 5NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models 2NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models 3NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models 4NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models 5
Super High Density, multi-frequency, convex array, small footprint transducer for scanning during craniotomies....
... is our High Penetration Steered Linear Peripheral ... 3 to 8 MHz. It is ... Harmonic Detection with 4 different settings to ... vessels. The high color and Doppler sensitivity ...
Super High Density, multi-frequency, end-fire phased array transducer. Point-and-shoot scanning is the benefit of this transducer....
HST, multi frequency Side Fire "T intraoperative transducer. A wide field of view is this transducers benefit....
Medicine Products: